Back to Search
Start Over
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis
- Source :
- Chest; November 2018, Vol. 154 Issue: 5 p1070-1082, 13p
- Publication Year :
- 2018
-
Abstract
- We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.
Details
- Language :
- English
- ISSN :
- 00123692 and 19313543
- Volume :
- 154
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Chest
- Publication Type :
- Periodical
- Accession number :
- ejs46557938
- Full Text :
- https://doi.org/10.1016/j.chest.2018.08.1029